Browse studies

Find your next paid study

17 recruiting studies matching your filters

A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap…

Breast CancerTNBC - Triple-Negative Breast CancerHER2-negative Breast Cancer

Estimated

~$10 – $8,750

Processa PharmaceuticalsNCT06568692

Phase 2

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which t…

Breast NeoplasmsBreast CancerBreast Tumors+8 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT01042379

Observational

NearWave Optical Molecular Monitoring for Predicting Complete Pathological Response (pCR) to Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients

The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pa…

Breast CancerHER2-positive Breast CancerTNBC - Triple-Negative Breast Cancer+2 more

Estimated

~$10 – $6,250

Indiana UniversityNCT06744465

Phase 2

IIT2024-02-SHIAO-ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progress…

TNBC - Triple-Negative Breast CancerBreast Cancer

Estimated

~$10 – $7,500

Stephen ShiaoNCT07015853

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided te…

TNBC - Triple-Negative Breast CancerMinimal Residual Disease

Estimated

~$10 – $1,050

Personalis Inc.NCT06230185